Non-small Cell Lung Cancer Market cover

Non-small Cell Lung Cancer Market by Histology (Large Cell Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma), Treatments (Chemotherapy, Surgery, and Radiation), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

  • Report ID: CG-2517
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 194
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global non-small cell lung cancer market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to the wide prevalence of lung cancer and increasing cases of HIV infection. The growth of the non-small cell drug cancer market is also attributed to the global increase in the population base.

Non-small Cell Lung Cancer Market summary

Lung cancer is categorized into two types namely small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The most number of lung cancer cases falls under the category of non-small cell lung cancer. When cancer cells start to form in the lung tissues, it is called non-small cell lung cancer. Some of the most commonly occurred symptoms are coughing up blood, chest pain, hoarseness, wheezing, loss of appetite, weight loss, shortness of breath, recurring bronchitis, fatigue, numbness of limbs, and difficulty in swallowing. Lung cancer can also be caused due to continued smoking cigars or pipes and cigarettes.  

As per the report by Cancer Research 2017, among the total 87% of the cancer patients present in the UK were non-small cell lung cancer patients. According to the report in 2019 by American Society of Clinical Oncology, 13% of all the new cancer diagnosis was related to lung cancer. The reports by the UK Cancer Research also stated that the number of cancer patients was increasing globally and expected to increase further in the near future. The reports estimated that if the growth rate of the cancer was at the same pace, the 27.5 million new global cancer cases were estimated to be reported by 2040.

Market Trends, Drivers, Restraints, and Opportunities

  • Rapid industrialization and increasing number of smokers globally are leading to sharp increase in air pollution. This is a key driver helping to grow the market.
  • Presence of well-structured and well-developed healthcare systems in various developed regions are expected to fuel the market growth in the coming years.
  • High cost of therapies and side effects caused by the existing drugs are acting as major restraints anticipated to impede the market growth during the forecast period.
  • Lack of awareness among people regarding non-small lung cancer is another key challenge that can hinder the market growth.
  • Ongoing research & development programs and growing investment in the development & launch of new products across the globe are estimated to present key opportunities for the market expansion.

Scope of the Report

The report on the global non-small cell lung cancer market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Non-small Cell Lung Cancer Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Histology (Large Cell Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma) and Treatments (Chemotherapy, Surgery, and Radiation)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Avastin; Gemzar; Merck KGa; Alimta; AstraZeneca; Taxotere; Roche; and Tarceva

Market Segment Insights

Large cell carcinoma segment is expected to dominate the market

On the basis of histology, the global non-small cell lung cancer market is categorized as large cell carcinoma, squamous cell carcinoma, and adenocarcinoma. The large cell carcinoma segment is expected to dominate the market during the forecast period since it can occur at any part of the lungs and is difficult to cure. Meanwhile, squamous cell carcinoma takes place in the middle of the lungs at squamous cells near the bronchus, and adenocarcinoma occurs at the outer parts of the lungs in the cells which secrets mucous. On the other hand, the adenocarcinoma segment is projected to grow at moderate rate when compared to the other two types.

Non-small Cell Lung Cancer Market types

Chemotherapy segment is anticipated to hold a key share of the market

Based on treatments, the market is segmented into chemotherapy, surgery, and radiation. The chemotherapy segment is anticipated to hold a key market share during the projected period owing to wide performed of the treatment method on a number of major therapies of cancer patients and wide availability of strong clinical performance. The use of platinum combination therapy is suggested by the American Society for Clinical Oncology for the treatment of first-line non-small cell lung cancer. For the first two phases of non-small cell, lung cancer surgery is used for its treatment. However, when surgeries are not possible for the first and second phase, then radiation is preferred to as the major treatment process. Due to which, the segment is projected to exhibit a high CAGR during the forecast period.

North America is projected to represent a substantial share

In terms of regions, the global non-small cell lung cancer market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to represent a substantial share of the market during the targeted period owing to early acceptance of innovative diagnostic techniques and wide adoption of advanced treatment devices by major players in the region. The market of North America is followed by Europe and rising number of habitual smokers in these regions prove to be major factors for driving the market. On the other hand, the market of Asia Pacific is expected to contribute a considerable market share in the coming years attributed to the wide prevalence of the disease in the region.   

Non-small Cell Lung Cancer Market region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Non-small Cell Lung Cancer Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Non-small Cell Lung Cancer Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Non-small Cell Lung Cancer Market - Supply Chain
  4.5. Global Non-small Cell Lung Cancer Market Forecast
     4.5.1. Non-small Cell Lung Cancer Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Non-small Cell Lung Cancer Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Non-small Cell Lung Cancer Market Absolute $ Opportunity
5. Global Non-small Cell Lung Cancer Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Non-small Cell Lung Cancer Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Non-small Cell Lung Cancer Demand Share Forecast, 2019-2026
6. North America Non-small Cell Lung Cancer Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Non-small Cell Lung Cancer Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Non-small Cell Lung Cancer Demand Share Forecast, 2019-2026
7. Latin America Non-small Cell Lung Cancer Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Non-small Cell Lung Cancer Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Non-small Cell Lung Cancer Demand Share Forecast, 2019-2026
8. Europe Non-small Cell Lung Cancer Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Non-small Cell Lung Cancer Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Non-small Cell Lung Cancer Demand Share Forecast, 2019-2026
9. Asia Pacific Non-small Cell Lung Cancer Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Non-small Cell Lung Cancer Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Non-small Cell Lung Cancer Demand Share Forecast, 2019-2026
10. Middle East & Africa Non-small Cell Lung Cancer Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Non-small Cell Lung Cancer Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Non-small Cell Lung Cancer Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Non-small Cell Lung Cancer Market: Market Share Analysis
  11.2. Non-small Cell Lung Cancer Distributors and Customers
  11.3. Non-small Cell Lung Cancer Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Avastin
     11.4.2. Gemzar
     11.4.3. Merck KGa
     11.4.4. Alimta
     11.4.5. AstraZeneca
     11.4.6. Taxotere
     11.4.7. Roche
     11.4.8. Tarceva

Segments Covered in the Report

The global non-small cell lung cancer market has been segmented on the basis of

Histology

  • Large Cell Carcinoma
  • Squamous Cell Carcinoma
  • Adenocarcinoma

Treatments

  • Chemotherapy
  • Surgery
  • Radiation

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Avastin
  • Gemzar
  • Merck KGa
  • Alimta
  • AstraZeneca
  • Taxotere
  • Roche
  • Tarceva

Key players competing in the global non-small cell lung cancer market are Avastin; Gemzar; Merck KGa; Alimta; AstraZeneca; Taxotere; Roche; and Tarceva. Many of these players have adopted business strategies such as launching of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their consumer base and expand their market position globally.

Non-small Cell Lung Cancer Market keyplayers

Buy Report